DataMeds AI, Inc.
Close on Oct 19, 2026
- Market cap
- $6.87M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 19, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 18, 2026 | Before market open | $1.78M | $-7.13 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 19, 2026 | After market close | $929.00K | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 20, 2025 | After market close | – | $-0.46 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 22, 2025 | After market close | – | – | – |
Company guidance
Outlook given with results on May 19, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue | Q2-2026 | $1.78M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements DataMeds AI filed with the SEC
AI. ACQUIRES HELOMICS AI CANCER DIAGNOSTICS LAB AND PRECISION ONCOLOGY CRO BUSINESSES FROM AXE COMPUTE
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
AI Reports Second Quarter 2026 Financials and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Holders of DataMEDS Holding Company Common Stock:
Other events · EX-99.1 to Form 8-K
of Datavault AI Inc. Opt-In Agreement
Other events · EX-99.2 to Form 8-K
REGARDING THE DISTRIBUTION OF DREAM BOWL 2027 MEME COINS BY DATAVAULT AI INC. TO COMMON STOCKHOLDERS OF DATAMEDS AI, INC
Other events · EX-99.3 to Form 8-K
DataMEDS AI Announces Updated August 7, 2026 Record
Other events · EX-99.1 to Form 8-K
HEALTH, INC. OFFICIALLY CHANGES CORPORATE NAME TO DATAMEDS AI, INC.
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Health Announces Lock-Up Agreement with Holders of a Majority of its Common Stock
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Health Releases Letter to Our Shareholders
Other events · EX-99.1 to Form 8-K
Health Reports First Quarter 2026 Financials and Provides
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Health to Announce First Quarter 2026 Financials on Tuesday May 19, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives
Material agreement · Listing notice · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K/A
Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Strengthens PharmacyChain™ with Insurance Eligibility & Benefits Verification Capabilities
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet™
Regulation FD disclosure · EX-99.1 to Form 8-K
Health to Add Telehealth & Mental Health AI Capabilities via Tollo Health Partnership Expansion
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Alumni Health Partners with Wellgistics Health to Deploy Technology to Improve Health Outcomes for Former NFL Players and Rural Communities
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Health Provides 2026 Corporate Outlook
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Health Reminds Shareholders of December 19, 2025 Record Date for Dream Bowl 2026 Meme Coin Tokens
Regulation FD disclosure · EX-99.1 to Form 8-K
Health Announces Launch of Diabetes Drug Brenzavvy ® to Wellgistics Pharmacy Network
Regulation FD disclosure · EX-99.1 to Form 8-K
Health Announces that it will Distribute a Dream Bowl 2026 Meme Coin to Wellgistics Health Stockholders
Regulation FD disclosure · EX-99.1 to Form 8-K
Health Announces Sponsorship of Dream Bowl 2026 and Participation in DataVault AI Dream Bowl 2026 Meme Coin Shareholder Distribution
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
AI Licenses Patents Covering Digital Ledger-enabled Smart Contracts for Commercial Prescription Drug Distribution Industry to Wellgistics
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K/A
AI Completes Exclusive License of Patents Covering Use of Blockchain-enabled Smart Contracts for Commercial Prescription Drug Distribution
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Health Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Health Enters into Smart Contract Services Agreement with DataVault AI to Develop Patented PharmacyChain™ Manufacturer-to-Patient
Regulation FD disclosure · EX-99.1 to Form 8-K
AI and Wellgistics Health Announce Plans for PharmacyChain ™ to Implement Manufacturer-to-Patient Blockchain-enabled
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Health Announces Executive Management and Board Changes
Regulation FD disclosure · EX-99.1 to Form 8-K
Health Announces Pricing of $5 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Health (NASDAQ:WGRX) and TheracosBio Partner to Expand Nationwide, PBM-Free Access to Brenzavvy(R), an FDA-Approved Diabetes Therapy,
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Health, Inc. to Present at September Investor Conferences
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Regulation FD disclosure · EX-99.3 to Form 8-K
Health Introduces HubRx AI: Advancing the AI-Powered Prescription Ecosystem
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Health Achieves Stability in First-Half 2025 and Executes Growth Initiatives
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Health (NASDAQ: WGRX) Launches XRP Payment Program for Independent Pharmacies
Agreement terminated · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Health Terminates Equity Line of Credit to Further Support Growth Strategy
Agreement terminated · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Health Converts $8.1M Debt to Equity
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
of Wellgistics Health Converts $1.5 Million of Debt to Equity at IPO Price
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K